Selecting the Best Combined Biological Therapy for Refractory Inflammatory Bowel Disease Patients.

Autor:	Mas, Eduard Brunet, Calvo, Xavier Calvet
Předmět:	INFLAMMATORY bowel diseases BIOTHERAPY CROHN'S disease ULCERATIVE colitis REFRACTORY materials
Zdroj:	Journal of Clinical Medicine; Feb2022, Vol. 11 Issue 4, pN.PAG-N.PAG, 1p
Abstrakt:	Current medical treatment for inflammatory bowel disease (IBD) does not achieve 100% response rates, and a subset of refractory and severely ill patients have persistent active disease after being treated with all possible drug alternatives. The combination of two biological therapies (CoT) seems a reasonable alternative, and has been increasingly tested in very difficult cases. The present review suggests that CoT seems to be safe and effective for refractory and severely ill IBD patients. Ustekinumab plus vedolizumab and vedolizumab plus anti-TNF were the most used CoTs for Crohn's disease. For ulcerative colitis, the most used CoTs were vedolizumab plus anti-TNF and vedolizumab plus tofacitinib. The aforesaid CoTs have shown good efficacy and few adverse events have been reported. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.